↓ Skip to main content

Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double‐blinded, placebo‐controlled, phase II clinical trial

Overview of attention for article published in Cancer Communications, December 2017
Altmetric Badge

Mentioned by

wikipedia
1 Wikipedia page

Citations

dimensions_citation
28 Dimensions

Readers on

mendeley
51 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double‐blinded, placebo‐controlled, phase II clinical trial
Published in
Cancer Communications, December 2017
DOI 10.1186/s40880-017-0263-y
Pubmed ID
Authors

Rui-Hua Xu, Lin Shen, Ke-Ming Wang, Gang Wu, Chun-Mei Shi, Ke-Feng Ding, Li-Zhu Lin, Jin-Wan Wang, Jian-Ping Xiong, Chang-Ping Wu, Jin Li, Yun-Peng Liu, Dong Wang, Yi Ba, Jue-Ping Feng, Yu-Xian Bai, Jing-Wang Bi, Li-Wen Ma, Jian Lei, Qing Yang, Hao Yu

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 51 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 16%
Student > Bachelor 4 8%
Student > Doctoral Student 3 6%
Lecturer 3 6%
Student > Master 3 6%
Other 5 10%
Unknown 25 49%
Readers by discipline Count As %
Medicine and Dentistry 7 14%
Nursing and Health Professions 6 12%
Biochemistry, Genetics and Molecular Biology 5 10%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Sports and Recreations 2 4%
Other 2 4%
Unknown 27 53%